Evidence map›Paper›PMID 27911851›Full record

ArticleOncotarget2016

Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.

Jennifer B Permuth, Brett Reid, Madalene Earp, Y Ann Chen, Alvaro N A Monteiro, Zhihua Chen, AOCS Study Group, Georgia Chenevix-Trench, Peter A Fasching, Matthias W Beckmann and 91 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

101 authors at 20 institutions in 11 countries.

Jennifer B PermuthDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Brett ReidDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Madalene EarpDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Y Ann ChenDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Alvaro N A MonteiroDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Zhihua ChenDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
AOCS Study GroupGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
Georgia Chenevix-TrenchGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
Peter A FaschingDavid Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
Matthias W BeckmannUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen, Germany.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium.
Adriaan VandersticheleDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Els Van NiewenhuyseDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Ignace VergoteDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer Anne DohertyDepartment of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NY, USA.
Jenny Chang-ClaudeGerman Cancer Research Center, Division of Cancer Epidemiology, Heidelberg, Germany.
Kirsten MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kunle OdunsiDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Marc T GoodmanCancer Prevention and Control, Samuel Oshin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yurii B ShvetsovCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Pamela J ThompsonCancer Prevention and Control, Samuel Oshin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Natalia BogdanovaRadiaton Oncology Research Unit, Hannover Medical School, Hannover, Germany.
Ralf ButzowDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Liisa PelttariDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Arto LeminenDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Francesmary ModugnoDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Robert P EdwardsDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Roberta B NessThe University of Texas School of Public Health, Houston, TX, USA.
Joseph KelleyDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Beth KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Graham GilesCancer Epidemiology Centre, Melbourne, Australia.
Michelle HildebrandtDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dong LiangCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.
Karen H LuDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Douglas A LevineGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria BisognaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
Shelley S TworogerDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Elizabeth M PooleChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Brooke FridleyDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Julie CunninghamDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Stacey J WinhamDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Sara H OlsonMemorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
Irene OrlowMemorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
Line BjorgeCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Lambertus A KiemeneyRadboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, Netherlands.
Leon MassugerRadboud University Medical Center, Radboud Institute for Molecular Life Sciences, Department of Gynaecology, Nijmegen, The Netherlands.
Tanja PejovicDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA.
Melissa MoffittDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA.
Nhu LeCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
Linda S CookDivision of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Angela Brooks-WilsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver BC, Canada.
Linda E KelemenDepartment of Public Health Sciences, Medical University of South Carolina College of Medicine, Charleston, SC, USA.
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Jan LubinskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, The Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
Hanna YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Estrid HogdallDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Claus HogdallThe Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark.
Lene LundvallThe Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark.
Paul D P PharoahDepartment of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Honglin SongDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Ian CampbellCancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
Diana EcclesFaculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK.
Iain McNeishInstitute of Cancer Sciences, Unversity of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, UK.
Alice WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Weiva SiehDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Joseph RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Catherine M PhelanDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Harvey RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Steven NarodWomen's College Research Institute, University of Toronto, Toronto, ON, Canada.
John McLaughlinPublic Health Ontario, Toronto, ON, Canada.
Hoda Anton-CulverDepartment of Epidemiology, Director of Genetic Epidemiology Research Institute, UCI School of Medicine, University of California Irvine, Irvine, CA, USA.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA.
Usha MenonDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Simon GaytherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Susan J RamusDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Aleksandra Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, London, UK.
Celeste Leigh PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Agnieszka Dansonka-MieszkowskaDepartment of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
Jin Q ChengDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Ellen L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Thomas A SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Moffitt Cancer Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Southern California · USNational Cancer Institute · USUniversity of Helsinki · FIBrigham and Women's Hospital · USCedars-Sinai Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh · USBC Cancer Agency · CAKU Leuven · BERadboud University Nijmegen · NLStanford University · USThe University of Melbourne · AUUniversity of California, Irvine · USUniversity of Hawaiʻi at Mānoa · USDartmouth College · USQIMR Berghofer Medical Research Institute · AURigshospitalet · DKRoswell Park Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 16561Medical Research Council G0501974NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA072720NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA149429NCI NIH HHS R01 CA160669NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA069417NCI NIH HHS U19 CA148112NCI NIH HHS UM1 CA176726NCRR NIH HHS M01 RR000056
6 · The paper itself

Abstract

RNA editing in mammals is a form of post-transcriptional modification in which adenosine is converted to inosine by the adenosine deaminases acting on RNA (ADAR) family of enzymes. Based on evidence of altered ADAR expression in epithelial ovarian cancers (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in ADAR genes modify EOC susceptibility, potentially by altering ovarian tissue gene expression. Using directly genotyped and imputed data from 10,891 invasive EOC cases and 21,693 controls, we evaluated the associations of 5,303 SNPs in ADAD1, ADAR, ADAR2, ADAR3, and SND1. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI), with adjustment for European ancestry. We conducted gene-level analyses using the Admixture Maximum Likelihood (AML) test and the Sequence-Kernel Association test for common and rare variants (SKAT-CR). Association analysis revealed top risk-associated SNP rs77027562 (OR (95% CI)= 1.39 (1.17-1.64), P=1.0x10-4) in ADAR3 and rs185455523 in SND1 (OR (95% CI)= 0.68 (0.56-0.83), P=2.0x10-4). When restricting to serous histology (n=6,500), the magnitude of association strengthened for rs185455523 (OR=0.60, P=1.0x10-4). Gene-level analyses revealed that variation in ADAR was associated (P<0.05) with EOC susceptibility, with PAML=0.022 and PSKAT-CR=0.020. Expression quantitative trait locus analysis in EOC tissue revealed significant associations (P<0.05) with ADAR expression for several SNPs in ADAR, including rs1127313 (G/A), a SNP in the 3' untranslated region. In summary, germline variation involving RNA editing genes may influence EOC susceptibility, warranting further investigation of inherited and acquired alterations affecting RNA editing.

Indexed as

AnimalsDisease SusceptibilityFemaleGenetic VariationHumansMiddle AgedOvarian NeoplasmsPolymorphism, Single NucleotideRNA Editingovarian cancer riskpolymorphismsRNA editing

Identifiers

PMID27911851
PMCPMC5340123
OpenAlexW2488838881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.